CED Digest: 230 Items — March 18, 2026

Alabama Medical Cannabis Sales Gear for Spring 2026 Launch

Alabama’s medical cannabis program is preparing to begin patient sales in spring 2026, requiring clinicians to understand regulatory requirements and patient access protocols for this emerging treatment market.

Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds

Cannabis cannabinoids CBD and CBG show potential therapeutic effects against fatty liver disease, relevant for clinicians considering cannabis-based treatment options for hepatic conditions.

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …

The article covers regulatory enforcement actions against cannabis beverage companies, illustrating the gap between market growth and FDA compliance—critical for clinicians advising patients on product safety and legality.

Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …

CBD and CBG cannabinoids demonstrated efficacy in reducing hepatic steatosis and improving metabolic markers, providing clinicians evidence-based data for therapeutic applications in liver disease management.

New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

New Top Cannabis Regulator Sets Priorities In First Board Meeting

A newly appointed cannabis regulatory leader outlined their initial priorities during their inaugural board meeting, establishing the regulatory direction that will affect clinical cannabis practice and patient access.

Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead

Brazil’s cannabis regulatory framework is evolving, addressing clinical applications while navigating implementation challenges relevant to medical practitioners prescribing cannabis therapeutically.

2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT

Two Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through litigation, raising legal questions about cannabis product regulation that clinicians should monitor for evolving state compliance requirements.

New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG

Ohio’s new law restricts THC-infused beverage distribution through retail channels, affecting product availability and patient access routes that clinicians may discuss with cannabis-using patients.

Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo

Oregon lawmakers rejected legislation that would have limited THC potency in cannabis edibles, leaving current unrestricted dosing standards in place for clinical and consumer products.

Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature

Oregon lawmakers rejected a bill to cap THC potency in cannabis edibles, leaving clinicians without regulatory limits when counseling patients on dosing safety and dependence risks.

Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health

Cannabidiol (CBD) and cannabigerol (CBG) demonstrate potential to reduce hepatic steatosis and improve metabolic parameters, relevant for clinicians evaluating cannabis therapeutics in metabolic disease management.

Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed

This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, relevant for clinicians developing alternative administration strategies beyond smoking or standard oral intake.

Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML

CBD-dominant cannabis products demonstrate efficacy for anxiety relief, providing clinicians with evidence-based data to inform patient treatment recommendations and product selection.

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing evidence-based data for clinicians treating musculoskeletal pain conditions.

As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely

A medical cannabis patient discusses a Supreme Court case’s implications for patient access and legal protections in clinical cannabis practice.

The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra

This legal column covers cannabis regulatory developments and compliance issues relevant to healthcare providers navigating evolving federal and state laws affecting clinical practice.

Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch

Marijuana gummies sold in Ohio were recalled; clinicians need awareness of product safety issues and recall information to counsel patients on safe consumption.

New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire

A new industry group has formed in preparation for Medicare’s planned CBD pilot programs, which could expand clinical cannabinoid access and insurance coverage for eligible patients.

Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA

This resource addresses legal prohibition frameworks affecting marijuana, relevant for clinicians understanding regulatory compliance and jurisdictional restrictions impacting patient care delivery.

Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries

A Louisiana legislator proposed legalizing recreational marijuana sales via licensed dispensaries, directly impacting clinical practice through expanded legal access and potential regulatory frameworks affecting patient care.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries

A Georgia mother’s homemade medical cannabis formulation has been commercialized and is now available at licensed dispensaries, demonstrating patient-developed preparations entering regulated medical markets.

Ohio THC drink ban draws lawsuit from Cincinnati breweries

Ohio’s THC beverage restrictions prompted legal challenges from breweries, relevant to clinicians managing cannabis product regulations and patient access to alternative consumption methods.

Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease

Israeli researchers identified cannabis compounds with potential therapeutic effects for fatty liver disease, representing the first possible drug development for this condition from cannabinoid research.

Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog

Virginia’s adult-use cannabis sales bills passed both legislative chambers and are proceeding to conference committee, potentially expanding legal cannabis access in the state.

Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown

This article examines research on medical marijuana’s therapeutic benefits and drawbacks while documenting Tennessee’s uncertain regulatory status for clinical cannabis implementation.

2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13

The 2026 Utah legislature addresses regulatory and legal frameworks for cannabis, psychedelics, and kratom, which directly impacts clinical practice, patient access, and prescribing guidelines for healthcare providers in the state.

Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails

Oregon’s proposed legislation to cap THC content in marijuana edibles at 10 milligrams per unit failed, maintaining current dosing standards that clinicians use for patient counseling and safety protocols.

Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube

A proposed Georgia law would restrict law enforcement from using the odor of cannabis, marijuana, or hemp as grounds for vehicle searches, affecting clinicians’ patients’ legal protections.

Study reveals cannabis compounds reduce threat of fatty liver disease | Health

Research demonstrates that specific cannabis compounds may decrease fatty liver disease risk, providing clinicians with evidence-based pharmacological mechanisms relevant to cannabis therapeutics and patient counseling.

Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR

Market analysis projects prescription CBD oil will reach $190.9 billion by 2032, indicating substantial industry growth that clinicians should understand for patient access and treatment landscape awareness.

TPS Cannabis News – StratCann

InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …

InMed Pharmaceuticals discontinued its partnership with BayMedica’s non-cannabinoid program, refocusing on therapeutic development—relevant for clinicians tracking cannabis company pipelines and available cannabinoid products.

Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots

Cannabis extracts demonstrated efficacy in reducing myofascial pain, providing clinicians with evidence-based data for treatment considerations in pain management protocols.

Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube

Pediatricians highlight cannabis use disorder in children and increased accessibility to the drug, relevant for clinicians treating cannabis-related conditions in younger populations.

West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …

West Virginia House advances legislation directing medical marijuana tax revenue allocation, affecting clinical program funding and operational resources for cannabis healthcare practitioners.

Study highlights positive, negatives of medical marijuana – WKRN News 2

A study examines both therapeutic benefits and risks of medical marijuana, providing clinical evidence relevant to prescribing decisions and patient safety monitoring.

The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News

This article examines roadside THC testing methods and Saskatchewan Government Insurance’s zero-tolerance impaired driving policy, relevant to clinicians assessing patient impairment and legal implications.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries

A Georgia mother’s homemade medical cannabis formulation has been commercialized and is now available at licensed dispensaries, representing patient-developed cannabis therapeutics entering regulated retail markets.

‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …

Tennessee legislation proposes legalizing marijuana while dedicating tax revenue to infrastructure repair, creating potential opportunities and regulatory frameworks relevant to clinical cannabis practice.

One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword

A major Colorado dispensary chain’s acquisition indicates consolidation in the legal cannabis market, relevant to clinicians tracking industry structure changes affecting patient access and product availability.

Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN

This article examines how cannabis legalization correlates with increased marijuana use among specific US adult populations, informing clinicians about shifting demographic patterns in patient populations and usage trends.

Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook

Ohio regulators recalled marijuana gummies missing required THC labeling symbols, ensuring products meet compliance standards for proper identification and patient safety.

Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon.

This study examines how Oregon adults perceive marijuana versus alcohol risk, providing clinicians evidence of public harm perceptions relevant to patient counseling and clinical decision-making.

What’s Really Happening With Cannabis ETF MSOS? – The Dales Report

**This article examines the MariMed Cannabis ETF (MSOS) performance and factors affecting cannabis industry investments, which matters to clinicians tracking commercial market trends influencing product availability and pricing.**

Study reveals cannabis compounds reduce threat of fatty liver disease – Daily Journal

Cannabis compounds may reduce fatty liver disease risk, providing clinicians with potential therapeutic applications for managing hepatic steatosis in patients.

Scientists are raising new concerns about marijuana use in teens – KPBS

Adolescent cannabis use is associated with increased psychiatric risks including psychosis, depression, and anxiety—critical knowledge for clinicians treating teen patients or advising on developmental vulnerabilities.

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

Cannabis extracts reduced myofascial pain in temporomandibular disorder patients, offering clinicians an evidence-based alternative for treating conditions resistant to conventional medications.

Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure

This article examines placental biomarkers as potential early indicators of schizophrenia risk following prenatal THC exposure, relevant to clinicians counseling pregnant patients about cannabis use.

Scientists are raising new concerns about marijuana use in teens – YouTube

Adolescent cannabis use poses clinical risks because THC exposure during brain development (through mid-twenties) associates with cognitive disruption, a critical consideration for patient assessment and counseling.

A huge study finds a link between cannabis use in teens and psychosis later – NPR

A large study demonstrates cannabis use during adolescence is associated with increased psychosis risk in adulthood, highlighting clinical importance of age-related vulnerability assessment.

Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape

Adolescent cannabis use is associated with increased risk for psychotic and bipolar disorders, information clinicians need when counseling teen patients about psychiatric consequences.

Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The Debrief

Recent research identifies the neurological mechanisms by which cannabinoids stimulate appetite, providing clinicians with scientific understanding to support evidence-based cannabis recommendations for appetite-related conditions.

Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds

Adolescent cannabis use significantly increases psychotic disorder risk in adulthood, requiring clinicians to assess developmental timing and brain vulnerability when evaluating cannabis-related psychiatric outcomes.

The association between cannabis use and brain reward anticipation: a 12-month … – Nature

This research examines how cannabis use affects brain reward processing, addressing inconsistent findings that are clinically relevant for understanding potential neurobiological impacts on motivation and pleasure responses.

THC levels in blood and urine are “unreliable” indicators of driving impairment – leafie

THC blood/urine levels don’t reliably predict driving impairment due to irregular distribution and metabolism, requiring clinicians to assess impairment through behavioral observation rather than test results alone.

Study Links Prenatal Cannabis Exposure To Schizophrenia – New Telegraph

Prenatal cannabis exposure may create placental biomarkers associated with schizophrenia risk in offspring, informing clinical counseling for pregnant patients considering cannabis use.

The Endocannabinoid System’s Contribution to Placebo Analgesia – bioRxiv

The endocannabinoid system mediates placebo analgesia, demonstrating that expectation-based pain relief operates through cannabinoid pathways, informing patient management and pain treatment mechanisms.

Modulating the endocannabinoid system in alcohol use disorder: A translational systematic …

This article examines how modulating the endocannabinoid system may address reward dysregulation, stress sensitivity, and impulse control deficits underlying alcohol use disorder, relevant to understanding cannabinoid therapeutic mechanisms.

Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The Hill

Cannabis hyperemesis syndrome causes cyclic severe nausea and vomiting in chronic heavy users, requiring clinicians to recognize and differentiate it from other gastrointestinal conditions for proper patient management.

Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online

This research compares cannabis use disorder’s psychiatric impact to other substance use disorders, helping clinicians assess relative clinical burden in evolving legal contexts.

Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …

This study presents evidence that lifetime cannabis use is not associated with cognitive decline or dementia in older adults, potentially informing clinical risk-benefit assessments for geriatric patients.

Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults

This study provides evidence that lifetime cannabis use does not accelerate cognitive decline in older adults, informing clinical risk assessment for this growing patient population.

Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease

Israeli researchers identified cannabinoid compounds effective against non-alcoholic fatty liver disease, potentially offering the first pharmaceutical treatment for a condition affecting hundreds of millions globally.

The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators

This article examines barriers preventing international cannabis companies from entering the U.S. market, relevant to clinicians understanding regulatory fragmentation affecting product availability and research access.

North Shore Dispensary opens in Duluth’s Lincoln Park – WDIO.com

A cannabis dispensary opened in Duluth’s Lincoln Park neighborhood, expanding retail access to legal cannabis products in the region.

Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic

Cannabis clinicians should note this research identifies cannabinoids’ potential mechanisms in reducing non-alcoholic fatty liver disease risk through hepatic inflammation and lipid metabolism modulation.

Observational study on medical marijuana use seeks Arizona participants – KJZZ

This article covers an observational study recruiting Arizona participants to generate real-world evidence on medical cannabis use across diverse patient conditions and consumption methods that controlled trials cannot capture.

Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC

Preclinical research indicates CBD and CBG may reduce hepatic fat accumulation through endocannabinoid receptor interactions, offering potential therapeutic applications for non-alcoholic fatty liver disease management.

A huge study finds a link between cannabis use in teens and psychosis later – KUOW

Longitudinal research demonstrates adolescent cannabis use correlates with increased psychosis risk in adulthood, important for clinicians assessing mental health vulnerability in young cannabis users.

Prescribed cannabis and driving behaviours among two samples of people who regularly … – UNSW

This research examines how medical cannabis affects driving safety by measuring THC’s impact on motor skills, reaction time, and judgment—critical for clinicians counseling patients on impairment risks.

Cannabis research: India to start human trials for medicinal marijuana – NewsBytes

India’s initiation of human clinical trials for medicinal cannabis will generate safety and efficacy data essential for evidence-based treatment protocols in regions with historically restrictive policies.

Cannabis Munchies Driven by Brain Reward Signals | Technology Networks

This article examines how cannabis activates brain reward pathways to trigger increased eating, helping clinicians better understand the neurological mechanisms behind cannabis-induced appetite stimulation in patients.

The association between cannabis use and brain reward anticipation: a 12-month … – Nature

This study examines how THC affects reward brain circuits during development over 12 months, informing clinicians about potential neurobiological changes relevant to cannabis use assessment and treatment planning.

Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis users

Cannabinoid hyperemesis syndrome causes severe cyclical vomiting in chronic cannabis users, and clinicians must recognize this paradoxical adverse effect to provide appropriate diagnosis and treatment guidance.

Study finds no links between cannabis use and cognitive decline or dementia in older people

Study challenges assumptions about cannabis causing cognitive decline or dementia in older adults, informing clinical risk discussions with elderly patients.

Cannabis Use and Brain Aging: What a Major Study Reveals – Born2Invest

This article examines whether cannabis use correlates with measurable changes in brain aging using biobank data—relevant for clinicians assessing long-term neurological effects on patients.

Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie

Older adults using cannabis show no accelerated cognitive decline or increased dementia risk versus non-users, challenging previous assumptions and informing clinical safety assessments.

Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com

Research indicates CBD and THC may reduce liver fat accumulation and inflammation in metabolic-associated steatotic liver disease, potentially expanding therapeutic applications beyond current clinical use.

Placental Changes From Prenatal Cannabis Exposure Could Flag Higher Schizophrenia …

Prenatal cannabis exposure produces epigenetic changes in placental tissue linked to neurodevelopmental pathways, providing clinicians evidence to discuss reproductive risks with patients of childbearing age.

Teens Who Use Cannabis Face Higher Risk Of Mental Disorders, Study Finds – Forbes

Adolescent cannabis use increases psychiatric disorder risk due to brain developmental vulnerability, requiring clinicians to implement early prevention and monitoring protocols. (38 words)

A huge study finds a link between cannabis use in teens and psychosis later – WBAA

A large study documents the association between adolescent cannabis use and increased psychosis and depression risk in adulthood, supporting clinical guidance against teen use during critical brain development.

Researcher: Remediated cannabis may still have harmful mold – MJBizDaily

Remediated cannabis may retain undetected mold despite passing state tests, posing infection risks to immunocompromised patients—critical knowledge for clinical prescribing decisions.

So, What Does an Adult at Low Risk of Cannabis Dependence Look Like?

This article identifies clinical risk factors for cannabis dependence in adults, helping physicians predict which patients can use cannabis safely and which require closer monitoring.

Cannabis hyperemesis syndrome cases surge in Virginia ERs – YouTube

Cannabis hyperemesis syndrome presents with cyclical vomiting and abdominal pain in frequent users; clinicians need awareness of this diagnosis to provide appropriate emergency care in legalized states.

Study Finds Veterans With SUD Used Cannabis to Alleviate Pain, Anxiety, and Improve Poor …

Veterans with SUD report using cannabis to manage pain, anxiety, and sleep during treatment, highlighting clinical patterns clinicians should recognize when treating this population.

ARTELO BIOSCIENCES, INC. SEC 10-K Report – TradingView

Artelo Biosciences develops targeted cannabinoid therapies for medical conditions like cancer-related anorexia and chemotherapy neuropathy, representing pharmaceutical advancement in endocannabinoid system research.

Bill to protect Nebraska physicians recommending medical cannabis advances to floor

Nebraska legislation protects physicians recommending medical cannabis from professional licensing consequences, removing a key barrier that previously deterred doctors from participating in cannabis treatment.

Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical …

This research examines how cannabis interacts with alcohol, caffeine, exercise, and sleep in affecting anxiety among medical students, providing clinicians evidence-based guidance for personalized anxiety management.

Nebraska bill to protect healthcare practitioners who recommend medical cannabis sails out of com…

Nebraska legislation protects healthcare practitioners recommending medical cannabis, aligning state regulation with voter-approved medical cannabis initiatives.

Major study finds strong link between cannabis, anxiety and depression – Medical Xpress

This article reports an observational study linking cannabis use with anxiety and depression, highlighting the challenge of determining whether cannabis causes these conditions or people with these conditions use cannabis more.

Research: Munchies May Aid Those Lacking Appetite – Pullman Today

Cannabis activates CB1 receptors in hunger-regulating brain regions, stimulating appetite—clinically relevant for patients with appetite loss from illness or treatment.

President Biden Signs Historic Cannabis Research Bill – Ganjapreneur

President Biden signed legislation removing federal barriers to cannabis research, enabling clinicians to conduct more rigorous clinical investigations into cannabinoid treatments.

Marijuana Use & Dangers for Adolescents & Young Adults

This article examines cannabis’s neurological impacts on developing brains through the mid-twenties and addresses cannabis use disorder in adolescents and young adults—critical knowledge for clinical assessment and treatment planning.

Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – KGET.com

Cannabis hyperemesis syndrome is a paradoxical condition causing severe nausea and vomiting in chronic heavy users; clinicians must recognize it to differentiate from other conditions and counsel patients appropriately.

Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent …

A Pediatrics study demonstrates that adolescent cannabis use—even at low frequency (monthly or less)—correlates with academic decline and disruptions, informing clinical risk assessment and counseling.

Pipeline Progress Drives Investor Focus at Agentix – Ad-hoc-news.de

Pharmaceutical companies are developing targeted cannabinoid drugs that modulate specific receptor pathways rather than whole-plant preparations, representing a clinical shift toward precision endocannabinoid system pharmacology.

Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORML

This research examines whether lifetime cannabis use is associated with cognitive decline or dementia risk in aging populations, informing clinical risk assessment and patient counseling.

Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML

CBD-dominant cannabis products demonstrate clinical efficacy for anxiety management, offering clinicians an evidence-based alternative treatment option with potentially fewer psychoactive side effects than THC-dominant formulations.

Toronto police shutdown multiple unlicensed cannabis dispensaries – CP24

Toronto police closed unlicensed cannabis dispensaries, affecting the legal supply chain and patient access to regulated, quality-assured products that clinicians recommend.

Using cannabis to cut back on alcohol? Your working memory might dictate if it works

This article examines the relationship between cannabis use, alcohol reduction, and working memory capacity, providing clinicians with information on individual factors affecting substitution outcomes.

Kentucky bill would change how alcohol, cannabis beverages are taxed – WKYT

Kentucky legislation proposes modifying tax structures for alcohol and cannabis beverages, which could affect product pricing, patient access, and dispensary economics in clinical cannabis settings.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries – WALB

A Georgia mother’s homemade medical cannabis recipe has entered commercial dispensary distribution, illustrating how patient-developed formulations are entering regulated markets and may inform clinical product standardization.

Teens Didn’t Just Discover Weed. So Why Is The Wall St. Journal Acting Like They Did?

This article critiques media sensationalism around teen cannabis use, examining why outlets overstate novelty in youth consumption trends—relevant to clinicians understanding accurate prevalence data for patient care and prevention strategies.

Exploring the Growing Trust in Cannabidiol Oil – The Assam Tribune

This article examines increasing consumer and professional confidence in cannabidiol (CBD) oil, relevant to clinicians evaluating CBD’s clinical applications and market perception trends.

Cannabis payouts drop for most Oakland County communities

Cannabis tax revenue distributions to Oakland County communities declined, affecting local funding for cannabis regulation, testing, and patient access programs that clinicians depend on.

New Cannabis Dispensary Opens On Route 22 In Somerville | Bridgewater, NJ Patch

A cannabis dispensary opened on Route 22 in Somerville, expanding retail access in the New Jersey market, which may affect patient availability and treatment options in the region.

Cannabis use by teenagers doubles their risk of developing psychotic and bipolar disorders

Cannabis use in teenagers is associated with doubled risk for psychotic and bipolar disorders, requiring clinicians to assess adolescent psychiatric vulnerability during cannabis counseling.

Pediatricians warn about cannabis use disorder, kids’ easy access to the drug

Pediatricians highlight cannabis use disorder in children and adolescents while noting accessibility barriers, informing clinical assessment and intervention strategies for youth populations.

Teen Cannabis Use May Double Your Risk of Psychosis and Bipolar

Adolescent cannabis use during critical neurodevelopmental periods increases psychiatric risk (psychosis, bipolar disorder) compared to adult use, requiring age-specific clinical assessment and patient counseling.

Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12–15 …

This article examines next-day driving safety after cannabis use, addressing a critical clinical concern for patient counseling and impairment assessment protocols.

Medicare may soon cover certain cannabis medications for seniors – MSU Denver RED

Medicare’s potential coverage of cannabis-based medications could expand treatment options for seniors managing chronic pain, sleep disorders, and neuropathic conditions, directly impacting clinical practice and patient access.

Placenta May Hide Early Warning Signs of Schizophrenia Risk – ScienceAlert

Prenatal THC exposure may create detectable placental biomarkers associated with schizophrenia risk, highlighting the importance of understanding cannabinoid effects on fetal development.

Bridging the Gap: Medical Cannabis, Regulators, and the Reality of Clinical Accountability

Medical cannabis prescribers face the same regulatory and accountability standards as other physicians, requiring documented clinical reasoning and patient safety practices.

Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News

This study documents concurrent increases in Canadian cannabis use and anxiety/depression diagnoses, providing clinicians evidence to inform patient assessments of mental health risk factors.

A Prescription Digital Therapeutic Framework for Enhancing Medical Cannabis Care

This article examines how prescription digital therapeutics can improve medical cannabis care through outcome measurement, personalized dosing, and structured clinical protocols for practitioners.

Ananda Pharma to Begin Dosing in NHS-Backed CBD Endometriosis Trial

Ananda Pharma is conducting an NHS-funded clinical trial testing CBD’s efficacy for endometriosis pain management, addressing an undertreated condition affecting millions of women globally.

Washington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In Hospitals

Washington State legislation permits terminally ill patients to use medical cannabis in hospitals, resolving conflicts between state cannabis law and facility policies affecting patient care options.

Natural Neuroprotection: Exploring the Potential of Non-Psychoactive Cannabinoids

This article examines how non-psychoactive cannabinoids interact with the endocannabinoid system to modulate neuroprotective mechanisms relevant to neurodegenerative diseases—key information for clinical cannabinoid therapeutics.

America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education …

This article examines gaps in medical education and research regarding cannabis, arguing that physician training deficiencies—not the plant itself—contribute to clinical management challenges.

Are My THC Gummies Going Away? – Science Friday

Federal regulators may restrict hemp-derived THC gummies, potentially affecting patient access to products currently used for clinical purposes under the 2018 Farm Bill loophole.

House panel approves proposed medical cannabis law – POLITIKO

The Philippines is advancing medical cannabis legislation to establish research infrastructure and regulated patient access, directly impacting clinical practice frameworks for healthcare providers.

What effects does THC have on youth who dabble? – YouTube

This article examines THC’s effects on adolescent neurodevelopment, particularly in the prefrontal cortex and limbic system—critical for clinical assessment of youth cannabis use risks.

Tennessee sisters fear new hemp law as CBD oils become harder to access – YouTube

Tennessee’s new hemp law restricts CBD oil access for patients with dystonia who have found therapeutic benefit from full-spectrum formulations containing multiple cannabinoids.

“Mother of Cannabinoids”: The Rising Potential of CBG and CBG-A – Cannabis Health News

CBG and CBGA are receiving research attention for potential therapeutic applications in anxiety, memory, and cancer, relevant to expanding cannabinoid treatment options for clinical practice.

Ghana launches medicinal cannabis programme under strict regulation

Ghana’s medicinal cannabis regulatory framework enables clinicians to access evidence-based cannabis therapeutics through structured programs and population-specific clinical data generation.

Patient Protect launches to tackle discrimination against UK medical cannabis patients

This article covers discrimination against UK medical cannabis patients in housing, employment, and driving, which clinicians should understand to better support patients navigating these barriers.

Study Links Rising Cannabis Use to Poor Mental Health – U.S. News & World Report

Research examines how cannabis use affects mental health outcomes in older adults, informing clinical treatment decisions for a population with unique metabolic considerations.

Natural Approaches to Managing Chronic Inflammation – WorldHealth.net

This article explains how the endocannabinoid system regulates inflammation through distributed receptors, and how plant cannabinoids like CBD and THC interact with these pathways.

Alabama medical cannabis program is now accepting patient registrations! – Blog

Alabama’s new medical cannabis program enables patient registration for qualifying conditions including chronic pain and PTSD, expanding treatment options for clinicians in a traditionally restrictive state.

House panel revives medical cannabis bill – Daily Tribune

The Philippines is developing regulated medical cannabis legislation, which matters to clinicians as it would establish legal frameworks for therapeutic cannabis prescribing in a previously restrictive jurisdiction.

More Kentucky children dying to ‘preventable’ overdoses, new report shows

This article reports increased pediatric cannabinoid overdoses in Kentucky, highlighting the need for improved safe storage practices to prevent accidental child exposure to cannabis products.

Legislation on medical cannabis: DOH bares conditions – Cebu Daily News

Philippine health authorities are establishing science-based regulatory conditions for medical cannabis legislation, directly impacting clinical access and treatment protocols for healthcare providers.

Sober shift could reshape spending, but doctor warns THC may be the new vice – Fox Baltimore

This article examines the public health implications of declining alcohol use paired with rising cannabis/THC consumption, highlighting clinical concerns about substance substitution patterns among Americans.

Secondhand marijuana smoke has fine particles that can cause asthma attacks and … – Instagram

Secondhand marijuana smoke contains fine particulate matter that triggers respiratory inflammation and asthma exacerbation, requiring clinicians to counsel patients on exposure risks.

Nebraska’s Medical Cannabis Commission holds hearing on emergency regulations – KETV

Nebraska’s medical cannabis commission is implementing a 90-day 5-gram THC possession limit, which clinicians should recognize may be insufficient for therapeutic dosing in many qualifying conditions.

Nebraska Bill Seeks To Shield Doctors Recommending Medical Cannabis From Arrest

Nebraska legislation would protect physicians recommending medical cannabis from criminal prosecution, enabling doctors to practice without legal liability concerns.

The Week in Weed: February 27, 2026 – Lexology

Research on acute physiological and psychoactive responses to cannabis use provides clinicians with evidence-based data to better assess and counsel patients about immediate cannabis effects.

First-of-its-kind long-term study at Virginia Tech shares how cannabis use can affect driving

This Virginia Tech study examines THC’s nonlinear effects on driving performance, addressing why standard impairment testing inadequately measures cannabis-related driving impairment—critical for clinical patient counseling.

Expert breaks down hidden dangers of doctors prescribing medical marijuana – UNILAD

This article examines Cannabis Use Disorder prevalence among medical marijuana patients and discusses clinical concerns about physician prescribing practices.

Hemp article tells us why WI needs government regulations | Letter – Milwaukee Journal Sentinel

Unregulated hemp-derived products lack standardized testing and labeling requirements, potentially exposing patients to undisclosed THC levels that could affect clinical outcomes and drug interactions.

Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law

This article covers medical cannabis use for drug-resistant childhood epilepsy, where cannabidiol has shown clinical efficacy—a key evidence-based application relevant to cannabis medicine practitioners.

New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

A new cannabis medicine group is advancing federally-grounded cannabinoid therapy policy using scientific evidence and patient data, directly influencing upcoming rescheduling discussions relevant to clinical practice.

Hey Sonar: Rethinking your relationship with weed – CSU Signal

‘Green lab’ helps Oregon officers recognize marijuana-impaired driving | The Astorian

Oregon law enforcement uses a “green lab” training program to identify impaired driving signs, which helps clinicians understand standardized assessment protocols for cannabis impairment evaluation.

Medical marijuana as someone working in healthcare industry : r/florida – Reddit

This Reddit discussion addresses employment considerations for healthcare workers seeking medical marijuana in Florida, relevant to clinicians navigating workplace policies and professional regulations.

Medical and recreational marijuana bills introduced in Kansas Legislature – KAKE

Kansas is considering medical and recreational cannabis legislation, which would provide clinicians with legal frameworks to treat qualifying patients in a previously prohibition-only state.

Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown

Medical cannabis legislation in Tennessee faces policy uncertainty despite growing Republican openness to reform and an established clinical evidence base for specific conditions.

The House Committee on Dangerous Drugs, together with the Committee on Health … – Facebook

The Philippine House is developing medical cannabis regulations and research provisions for qualified patients, directly affecting clinical practice standards and therapeutic access in the region.

Health advocate underscores ‘real danger’ in medical cannabis legalization in PH

This article examines regulatory and healthcare infrastructure challenges the Philippines faces in implementing medical cannabis oversight, directly relevant to clinical practice standards and patient safety frameworks.

Extended moratorium on Oklahoma medical marijuana business licenses approved by House

Oklahoma’s House approved extended moratorium on new medical marijuana licenses to address market oversaturation and regulatory challenges affecting patient access to quality cannabis products.

MS Senate committee approves one medical marijuana bill, rejects another

Mississippi’s Senate committee is debating medical cannabis access criteria, including which patient populations qualify and whether clinical administration in hospitals is permitted.

Major Canadian Study Reveals Significant Connection Between Cannabis Use, – Bioengineer.org

This research documents the bidirectional relationship between cannabis use and mood disorders, essential for clinicians assessing causation versus self-medication patterns in patient histories.

DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider

Sublingual/buccal thin-film delivery bypasses first-pass liver metabolism, potentially accelerating CBD onset and improving absorption consistency compared to oral cannabinoids.

420 with CNW – Texas Grapples with Increasing Cases of Marijuana DUI

This article addresses THC’s impairment of driving-critical functions and the absence of standardized blood THC thresholds, which are clinically relevant for patient safety counseling and legal implications.

Recreational Marijuana – Cons | Britannica

This article examines the pharmacological interaction between cannabis and alcohol, which is clinically relevant for assessing substitution effects and potential therapeutic applications in substance use management.

Feds warn about medical cannabis & hemp in drug tests (Newsletter: March 6, 2026)

Federal agencies warn that drug tests cannot reliably distinguish medical cannabis use from legal hemp products, creating compliance challenges for clinicians treating patients subject to workplace or legal drug testing.

Recreational Marijuana – Cons | Britannica

This article presents counterarguments to recreational marijuana legalization, providing clinicians with evidence-based concerns relevant to patient counseling and public health advocacy.

These Maine towns have the most cannabis businesses – The County

This article identifies Maine municipalities with the highest concentration of cannabis retail operations, providing clinicians with geographic data on patient access to legal dispensaries in their region.

DOH sets conditions on proposed medical cannabis legalization | Philippine News Agency

The Philippine DOH is developing medical cannabis legalization with patient access pathways, research expansion, and regulatory oversight—relevant for clinicians seeking formal treatment frameworks.

Building a global standard for cannabis vapes one terpene at a time – MJBizDaily

This article addresses efforts to establish global quality standards for cannabis vape products based on terpene profiles, which clinicians need to understand for consistent patient outcomes and dosing.

Cooney introduces bill to allow selling of low-potency cannabis beverages at liquor and wine stores

This covers regulatory approval of low-dose THC beverages (≤5mg/serving) in retail settings, clinically relevant because beverage pharmacokinetics differ significantly from inhalation routes regarding onset, absorption, and metabolism.

How a virtual medical cannabis clinic is working on healthcare coverage for THC

Virtual medical cannabis clinics are exploring insurance coverage for THC-based treatments as a potential cost-reduction strategy in healthcare systems.

New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery

Poland’s medical cannabis market recovered after telemedicine restrictions were imposed, requiring in-person consultations—clinicians should monitor regulatory changes affecting patient access pathways.

DPH Commissioner goes ‘On the Record’ about measles outbreaks, cannabis – YouTube

Public health officials warn about increased THC potency in legal cannabis products and adolescent exposure risks, relevant to clinicians assessing patient safety and developmental impacts.

The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators

The U.S. federal-state cannabis regulatory split complicates international pharmaceutical development and market access for cannabinoid medicines that clinicians might otherwise prescribe.

Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead

Brazil’s updated cannabis framework integrates medical cannabis into formal healthcare with domestic cultivation oversight and explicit THC product regulations, enabling clinicians to prescribe within a regulated system.

Branford industrial site sold, to become cannabis growing operation – The Wilton Bulletin

An industrial site in Branford was sold and will be converted to a cannabis growing operation, relevant to clinicians tracking local cultivation capacity and potential supply implications.

Most cannabis users are ‘non-problematic’, Canadian data shows – leafie

This article presents Canadian data demonstrating most cannabis users don’t develop problematic patterns, helping clinicians distinguish typical use from disorder and address stigma-related barriers to patient care.

US Cannabis Rescheduling: A Victory or a Federal Trap?

Federal rescheduling of cannabis from Schedule I to III affects regulatory oversight and legal status of medical programs, requiring clinicians to understand evolving FDA authority and compliance implications.

Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform

Rapid Dose Therapeutics is developing QuickStrip oral thin films for cannabinoid delivery to improve dosing precision and faster symptom onset compared to current administration methods.

Scientists Reveal What Types Of Food The Marijuana ‘Munchies’ Make You Crave The Most

Cannabis clinicians can use evidence that THC increases cravings for high-calorie, palatable foods to counsel patients on nutrition management and dietary planning during treatment.

Key Congressional Committee Set To Vote On Delaying Federal Hemp THC Ban Next Week

This covers congressional efforts to delay federal restrictions on hemp-derived THC products, relevant to clinicians due to regulatory uncertainty affecting patient access and product safety standards.

Wisconsin Democrats File Bill to Legalize Adult-Use, Medical Cannabis; Regulate Intoxicating Hemp

Wisconsin Democrats proposed legislation legalizing adult-use and medical cannabis while regulating intoxicating hemp products, establishing formal medical program oversight under state health services.

Rare Cannabinoid Company Expands Mood Collection with New THC-Free CBC Gummies …

This article covers CBC, a non-intoxicating cannabinoid with distinct endocannabinoid mechanisms, relevant to clinicians expanding THC-free therapeutic options beyond CBD.

Maryland Senate Delays Vote on Bill Allowing Firefighters to Use Medical Cannabis Off-Duty

Maryland Senate delays vote on medical cannabis use by off-duty firefighters, relevant to clinicians treating first responders with pain, PTSD, and sleep disorders.

Upper Township unanimous for weed zone, overriding complaints from residents

Upper Township unanimously approved a cannabis retail zone despite resident opposition, affecting where clinicians can legally refer patients for cannabis products and services.

Medical cannabis delivery app seeing growth in the DMV and Jamaica | DC News Now

Medical cannabis delivery apps expand patient access to medicine for those with mobility or health limitations, representing a regulatory and operational shift in dispensary models.

Cannabis industry launches organization to further US policy changes with members from …

Cannabis industry leaders formed a cross-border organization to influence US federal rescheduling policy, which directly impacts regulatory clarity and access for both patients and producers.

The Best CBD for Seniors in 2026: Safe, Lab-Tested, and Easy to Use | stupidDOPE

This article reviews CBD products for seniors, addressing a growing clinical demographic using cannabinoids for pain, sleep, anxiety, and inflammation management without psychoactive effects.

Indiana lawmakers miss deadline, killing key cannabis bill | News | wthitv.com

Indiana missed a procedural deadline on cannabis reform legislation, leaving the state’s medical cannabis policy unchanged while neighboring states expand patient access programs.

Hemp products had illegal THC amounts, mold, pesticides, and carcinogens, investigation finds

Unregulated hemp products often contain mislabeled THC levels and dangerous contaminants, requiring clinicians to counsel patients on quality verification and potential health risks.

Many NC candidates support medical marijuana legalization | Raleigh News & Observer

North Carolina candidates increasingly support medical marijuana legalization, reflecting growing bipartisan momentum that could expand patient access in one of the few remaining states without legal medical cannabis programs.

Does Weed Make You Harder or Easier to Manipulate? – Herb

Cannabis impairs prefrontal cortex function dose-dependently, affecting judgment and decision-making—critical knowledge for clinicians assessing cognitive impacts and counseling patients on usage risks.

Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know

Aelis Farma withdrew a clinical trial for AEF0117, a selective CB1 receptor inhibitor targeting THC adverse effects, affecting potential treatment options for cannabis use disorder.

Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings … – Newswire

This article discusses how Trump’s executive actions on cannabis scheduling may create regulatory clarity for pharmaceutical-grade cannabis manufacturers operating internationally, affecting clinical practice standards.

Veterans Groups Urge Congress To Expand Psychedelics And Marijuana Access To …

Veterans organizations advocate for VA access to cannabis and psychedelic therapies to address high veteran suicide rates, reflecting emerging clinical evidence supporting these treatments.

The Fire Station partners with Citizens for a Safe & Clean Lake Superior for cannabis vape …

The Fire Station cannabis retailer partnered with a local environmental organization, likely addressing product safety, environmental concerns, or community health standards relevant to cannabis vape products.

Boulder and CBD: The Entourage Effect Explained | About Boulder County Colorado

**Full-spectrum cannabis formulations containing multiple cannabinoids, terpenes, and flavonoids may produce superior therapeutic outcomes compared to isolated compounds, which is clinically relevant for treatment optimization.**

Indiana S.B. 250 could close Lafayette hemp-beverage sales without a key amendment

Indiana S.B. 250 could ban hemp-derived cannabinoid beverages, affecting patients currently using regulated products for symptom management without specific legislative amendments.

The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008

This article reviews CBD’s interaction with the endocannabinoid system for immune and stress regulation—relevant for clinicians evaluating cannabinoid-based treatment options for inflammation and homeostatic imbalances.

Louisiana Lawmakers Advance Adult-Use Cannabis Pilot Bill – KQKI News

Louisiana is establishing a limited adult-use cannabis pilot program to collect regulatory data on sales and consumption patterns in a traditionally restrictive state.

As Congress debates hemp-derived THC ban, Pa. lawmakers look for other options

Pennsylvania lawmakers are developing regulatory frameworks for hemp-derived THC products to address the legal ambiguity created by the 2018 Farm Bill’s undefined status of intoxicating hemp products.

West Virginia House approves bill allowing medical cannabis edibles | WV News

West Virginia approved medical cannabis edibles, expanding patient access to alternative delivery methods beyond smoking for treating various conditions.

The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com

Alabama’s medical cannabis program launching in April will enable clinicians to treat qualifying patients with conditions like chronic pain and PTSD using cannabis as a therapeutic option.

Branford industrial site sold, to become cannabis growing operation – New Haven Register

An industrial site in Branford was sold and will be converted into a cannabis cultivation facility, representing expansion of legal cannabis production infrastructure in Connecticut.

Utah Lawmakers Pass Bill To Support Clinical Trials On Psychedelics For Veterans’ Mental Health

Utah lawmakers approved legislation enabling psychedelic clinical trials for veterans with mental health conditions, expanding research options beyond cannabis for treating PTSD and trauma-related disorders.

The Best CBD for Mental Clarity and Focus in 2026 | stupidDOPE | Est. 2008

This article reviews CBD’s mechanisms of action on multiple receptor systems relevant to cognitive and mood outcomes, providing evidence-based information for clinical decision-making.

Study uncovers another reason not to skimp on sleep – ASU News

Sleep deprivation impairs prefrontal cortex function, increasing impulsive decision-making and substance use risk—clinicians should assess sleep quality when treating cannabis use disorders.

OCM issues precautionary recall for select cannabis products tested by Keystone Lab – CBS 6 Albany

The OCM’s precautionary recall of cannabis products due to testing integrity concerns highlights the critical role of reliable third-party lab verification in ensuring product safety for clinical and consumer use.

High Tide joins U.S. National Compassionate Care Council | HITI Stock News

High Tide’s involvement in the National Compassionate Care Council advances standardized medical cannabis access protocols, benefiting clinicians through more consistent evidence-based regulatory guidance.

Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply

Oklahoma’s rapid medical cannabis expansion revealed regulatory gaps in dispensary oversight, product consistency, and diversion prevention, prompting policy reconsideration relevant to clinical practice standards.

SA risks missing R40bn hemp industry opportunity without coherent strategy – Business Day

South Africa’s hemp industry lacks regulatory coordination needed to capture a R40 billion opportunity, affecting supply chains for CBD-based clinical products and raw materials.

Kearney man charged with selling THC cartridges to undercover officer near school – Nebraska TV

A Kearney, Nebraska resident faced charges for selling THC cartridges to an undercover officer near a school, illustrating law enforcement’s focus on illegal cannabis product distribution and school-proximity violations.

The Office Is Issuing A Recall On Multiple Adult-Use Cannabis Products Tested By Keystone …

This article covers regulated cannabis product recalls due to testing failures—relevant to clinicians for patient safety guidance on contaminated or mislabeled products in their practice.

Linnea Achieves CEP Certification for Cannabidiol Isolate – Morningstar

Linnea obtained European pharmaceutical-grade certification for CBD isolate, ensuring standardized identity, purity, and manufacturing consistency—critical for clinicians requiring reliable, regulated cannabinoid products.

Substance use on the rise among Gen Z in their early 20s – Medical Xpress

This article reports increased substance use among young adults in their early 20s, relevant to cannabis clinicians for understanding prevalence trends and clinical presentations in this demographic.

Senate Bill would repeal 24% wholesale tax on marijuana – WTVB

A Senate bill seeks to repeal a 24% wholesale marijuana tax implemented January 1, 2026, potentially affecting product pricing, patient access, and dispensary economics.

R40bn opportunity for hemp industrialisation in South Africa requires policy support – LSF study

This study quantifies a R40 billion industrial hemp opportunity for South Africa, relevant to clinicians as regulatory expansion may increase cannabis product availability and research funding.

Bill to require stricter packaging requirements for marijuana edibles dies in Oregon legislature

Oregon legislation requiring individual wrapping and standardized dosing for cannabis edibles failed to advance, affecting product safety standards and accidental exposure prevention in clinical settings.

Germany’s Medical Cannabis Boom: Data-Driven Insights for Investors | INN

Germany’s medical cannabis market growth is analyzed through real-world patient data, offering clinicians evidence-based insights into therapeutic effectiveness and treatment outcomes.

New study reveals how many Americans use CBD — and why | GreenState

This study provides epidemiological data on CBD usage patterns and demographics among Americans, helping clinicians understand patient prevalence, indications, and population trends for clinical practice.

New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery

Poland’s medical cannabis market recovery demonstrates regulatory progress in European medical cannabis access, providing clinicians with insights into post-legalization patient treatment patterns and market dynamics.

Wisconsin Democrats Introduce Cannabis Legalization Bill – Law360 Tax Authority

Wisconsin Democrats introduced recreational cannabis legalization legislation with regulatory and tax frameworks, relevant to clinicians for understanding evolving legal status affecting patient access and clinical practice.

CBD oil restores quality of life for sisters, sharing concerns about new regulations with hemp …

Two sisters report improved quality of life with THCA-containing CBD products while expressing concerns about regulatory restrictions that could affect patient access to hemp-derived therapeutics.

ACLU previews cannabis & guns arguments for Supreme Court (Newsletter: February 26, 2026)

The ACLU is challenging federal cannabis prohibition’s use to deny gun rights to state-legal users, creating legal ambiguity clinicians must navigate when documenting patient cannabis use.

Texas Voters Disapprove Of How State Officials Are Handling Marijuana And THC Laws, Poll Shows

Texas voters disapprove of state marijuana and THC regulation management, highlighting legislative inconsistencies in hemp-derived THC products that affect clinician compliance and patient access frameworks.

Bridging the Gap: Medical Cannabis, Regulators, and the Reality of Clinical Accountability

March 5 webinar offers parents lessons on drug/alcohol trends – Rice County, MN

A Rice County webinar educates parents on youth cannabis use trends and health impacts, helping clinicians understand community awareness and prevention messaging that may affect patient education and family discussions.

Michigan’s Marijuana Tax Experiment Should Be An Urgent Warning To Other States (Op-Ed)

Michigan’s high cannabis taxes are driving consumers to illegal markets, reducing legal sales and potentially affecting patient access to regulated, quality-controlled products.

Curaleaf Earnings: International Growth Offsets Domestic Decline from Continued Price Compression

Curaleaf’s earnings show legal cannabis market pressures from price competition and unregulated THC products, affecting industry viability and potentially patient access to regulated medical cannabis.

Kentucky bill would expand cannabis drink sales beyond liquor stores – WKYT

Senate Bill 223 establishes regulatory licensing for Kentucky cannabis-infused beverages, expanding retail distribution channels beyond liquor stores, affecting clinicians’ patient education about product accessibility and dosing consistency.

Advanced drug testing improves patient care at MUSC

MUSC’s advanced drug testing detects THC exposure more accurately and affordably than traditional methods, enabling clinicians to better assess patient cannabis use and personalize treatment.

As lawmakers in Richmond continue debating a path forward for retail marijuana sales …

Virginia lawmakers debate retail marijuana regulations despite lacking state-specific research on health impacts, creating evidence gaps that clinicians need to inform patient care decisions.

Europe’s Medical Cannabis Market Surges Toward $13 Billion: Last Week in Weed Feb. 23 …

Europe’s medical cannabis market growth to $13 billion reflects expanding regulatory frameworks and commercial availability, directly affecting clinician access to cannabis products and treatment options for patients.

Facing Hemp Ban, PA Lawmakers Race to Regulate THC Drinks and Products

Pennsylvania is developing regulations for THC-infused hemp products amid increased federal enforcement, affecting clinicians’ ability to counsel patients on legal product availability and potency standards.

Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws

Senator Ricketts declined to support federal protection for Nebraska’s medical cannabis program, leaving state practitioners uncertain about federal enforcement risks to their patients’ treatment access.

The Wait is Over: Medical Cannabis set to roll out in April | WKRG.com

Alabama’s medical cannabis program launches in April with dispensary sales, providing clinicians access to a regulated therapeutic option for eligible patients in their state.

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …

The FDA is escalating enforcement against cannabis beverage companies making unsupported health claims, creating regulatory and liability implications clinicians should monitor when counseling patients.

Popular Diabetes Drugs May Help Combat Multiple Addictions, Major Study Shows

GLP-1 receptor agonists (diabetes medications like semaglutide) demonstrate efficacy in treating multiple substance use disorders, potentially offering new pharmacological intervention options for patients with concurrent addiction and metabolic conditions.

The digest reflects growing clinical interest in cannabinoid therapeutics for metabolic and pain-related conditions, with multiple items documenting potential benefits of CBD and CBG in liver disease management and anxiety relief. Concurrently, regulatory frameworks are evolving unevenly across jurisdictions, creating significant inconsistencies in product availability and potency standards that complicate clinical guidance to patients. These parallel developments underscore the need for standardized formulations, consistent dosing guidelines, and coordinated regulatory approaches to support evidence-based clinical practice as cannabinoid products become more prevalent in medical settings.